NEWTON, Mass.--(BUSINESS WIRE)--March 30, 2006--Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that it has initiated patient enrollment in a pivotal Phase 3 clinical research study of vilazodone, a novel dual serotonergic antidepressant compound being studied for treatment of depression. The Company anticipates having initial results from this study available by mid-2007 and anticipates at least one long-term safety study and one additional pivotal study will be required prior to filing a New Drug Application (NDA).
